<DOC>
	<DOCNO>NCT00710528</DOCNO>
	<brief_summary>The purpose study determine dose safely give see effect may cancer determine drug distribute body .</brief_summary>
	<brief_title>Dose Escalation Study CAL-101 Select Relapsed Refractory Hematologic Malignancies</brief_title>
	<detailed_description>A Phase 1 , sequential dose escalation follow cohort expansion study CAL-101 , oral inhibitor PI3K delta , patient relapse refractory CLL , select B-cell NHL AML .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>1 . Age &gt; = 18 . 2 . Has relapse refractory disease define follow : CLL refractory relapse least 2 prior therapy , include fludarabine , alone combination . Patients eligible transplantation ( patient candidate transplantation decline transplantation eligible study ) . Bcell NHL refractory relapse least 1 prior chemotherapy regimen receive rituximab single agent combination therapy . AML refractory relapse least 1 cycle induction chemotherapy . Patients age 70 appropriate candidate chemotherapy eligible study . MM refractory relapse least 2 prior chemotherapy regimen , include bortezomib thalidomide lenalidomide ( except drug contraindicate patient requirement waive ) . 3 . Disease status requirement : For CLL patient , symptomatic disease mandate treatment . For Bcell NHL patient , measurable disease CT scan . For AML patient , &gt; 10 % blast bone marrow refractory relapse disease &gt; 20 % blast bone marrow prior chemotherapy . For MM patient , measurable disease define least 1 follow 3 measurement : serum Mprotein &gt; = 1 g/dL , urine Mprotein &gt; = 200 mg/24 h , serum free light chain ( FLC ) assay involve FLC level &gt; = 10 mg/dL provide serum FLC ratio abnormal . 4. WHO performance status â‰¤ 2 . 5 . For men woman childbearing potential , willing use adequate contraception ( i.e. , latex condom , cervical cap , diaphragm , abstinence , etc . ) entire duration study . 6 . Is able provide write informed consent . 1 . Had radiotherapy , radioimmunotherapy , biological therapy , chemotherapy , treatment investigational product within 4weeks prior screening . 2 . For CLL NHL patient , treatment short course corticosteroid symptom relief within 1week prior screening . 3 . Had alemtuzumab therapy within 12weeks prior screening . 4 . For AML patient , treatment hydroxyurea within 1week prior screening . 5 . Is pregnant nursing . 6 . Has significant , ongoing comorbid condition would preclude safe delivery study drug . 7 . Has transplant current active graftversushostdisease . 8 . Has know active central nervous system involvement malignancy . 9 . Has active , serious infection require systemic therapy . Patients may receive prophylactic antibiotic antiviral therapy discretion treat physician . 10 . Has significant renal liver dysfunction . 11 . Has severe thrombocytopenia require platelet transfusion support , unless diagnosis AML . 12 . Has positive test human immunodeficiency virus ( HIV ) antibody . 13 . Has active hepatitis B C. Patients serologic evidence prior exposure eligible . 14 . Has poorly control diabetes mellitus . 15 . Has take medication potent inhibitor inducer cytochrome P450 3A4 within 1week prior screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>CLL</keyword>
	<keyword>NHL</keyword>
	<keyword>AML</keyword>
	<keyword>MM</keyword>
	<keyword>Phosphatidylinositol 3-kinase</keyword>
</DOC>